LPS-Induced Inflammatory Diseases
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".
Deadline for manuscript submissions: 10 May 2026 | Viewed by 708
Special Issue Editors
2. A4245-Transplantation, Immunology and Inflammation, Faculty of Medicine, University of Tours, Tours, France
3. School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds, UK
Interests: ROS-sensitive calcium channels; oxidative stress calcium signaling; neuroinflammation; stroke; neurodegeneration; depression
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Lipopolysaccharide (LPS), a key component of the outer membrane of Gram-negative bacteria, is a potent inducer of inflammation and has been widely used as a model to study inflammatory diseases. LPS triggers the activation of Toll-like receptor 4 (TLR4) and the release of pro-inflammatory cytokines, oxidative stress, and immune dysregulation, contributing to the pathogenesis of conditions such as sepsis, acute lung injury, neuroinflammation, and metabolic disorders. Despite significant progress in understanding LPS-induced signaling pathways, effective therapeutic strategies to mitigate excessive inflammation remain elusive. This Special Issue aims to gather cutting-edge research and reviews on the molecular mechanisms underlying LPS-induced inflammation, novel anti-inflammatory targets, biomarker discovery, and potential therapeutic interventions. By addressing these aspects, this issue will provide valuable insights into the development of targeted therapies for inflammatory diseases driven by bacterial endotoxins.
Dr. Lin-Hua Jiang
Dr. Pankaj Kumar
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lipopolysaccharide (LPS)
- endotoxemia
- inflammation
- LPS signaling
- acute lung injury
- inflammatory cytokines
- therapeutic targets
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
